Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 11/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5733009 | 0.82 | GSK3B (0.40) | PRSS1CTSGCTRB1CMA1KDM4E | |
| SCHEMBL5844667 | 0.82 | KIF11 (0.37) | GPR119 | |
| SCHEMBL2844018 | 0.82 | SLC7A5 (0.37) | GAACTSSCTSK | |
| SCHEMBL4937584 | 0.82 | DPP4 (0.42) | MAPTL3MBTL1CTSSCTSK | |
| SCHEMBL27665873 | 0.82 | DPP4 (0.42) | MAPTL3MBTL1CTSSCTSK | |
| SCHEMBL27564999 | 0.82 | DPP4 (0.42) | MAPTL3MBTL1CTSSCTSK | |
| SCHEMBL25220978 | 0.81 | SMN1; SMN2 (0.38) | MAPTCTSSCTSK | |
| SCHEMBL390626 | 0.81 | CYP3A4 (0.43) | MAPTADRB2 | |
| SCHEMBL8015868 | 0.81 | PRSS1 (0.40) | PRSS1CTSGCTRB1CMA1KDM4E | |
| SCHEMBL1147794 | 0.81 | CYP3A4 (0.43) | MAPTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101090631-A | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIV SOUTHERN CALIFORNIA (US) | 2007-12-19 | — | — | CN | claimed |
| EP-1816913-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006091246-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2006-08-31 | — | — | WO | claimed |
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-06-29 | — | — | US | claimed |
| EP-3774722-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | Epiodyne, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019195634-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20110275646-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| US-7947682-B2 | Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-02-10 | — | — | US | disclosed |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-05-13 | — | — | US | disclosed |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
| CN-101090631-A | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIV SOUTHERN CALIFORNIA (US) | 2007-12-19 | — | — | CN | disclosed |
| US-20060235034-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-10-19 | — | — | US | disclosed |
| WO-2006091246-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-06-29 | — | — | US | disclosed |
| US-6610882-B2 | Affinity for bradykinin receptors; antithrombotics | SANOFI-SYNTHELABO (FR) | 2003-08-26 | — | — | US | disclosed |
| US-20030073641-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2003-04-17 | — | — | US | disclosed |
| US-20020115685-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-08-22 | — | — | US | disclosed |
| US-6433185-B1 | ANTIINFLAMMATORY AGENTS; ANALGESICS | SANOFI-SYNTHELABO (FR) | 2002-08-13 | — | — | US | disclosed |
| US-6313120-B1 | TREATMENT OR PREVENTION OF DISEASES INVOLVING BRADYKININ RECEPTORS | SANOFI-SYNTHELABO (FR) | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115685-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | CYP2C9, ADRM1, ADRA1D | PRSS1 740/4885CTSG 2758/4885CTRB1 1473/4885 |
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | VEGFA, TEK, LIPG | PRSS1 3120/4885CTSG 1498/4885CTRB1 3256/4885 |
| US-20110275646-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | VEGFA, TEK, LIPG | PRSS1 3120/4885CTSG 1498/4885CTRB1 3256/4885 |
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | VEGFA, TEK, MCL1 | PRSS1 2940/4885CTSG 1162/4885CTRB1 3203/4885 |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | VEGFA, TEK, MCL1 | PRSS1 2940/4885CTSG 1162/4885CTRB1 3203/4885 |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | VEGFA, TEK, MCL1 | PRSS1 2940/4885CTSG 1162/4885CTRB1 3203/4885 |
| US-20030073641-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | CYP2C9, ADRM1, ADRA1D | PRSS1 740/4885CTSG 2758/4885CTRB1 1473/4885 |
| US-20060235034-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | VEGFA, TEK, MCL1 | PRSS1 2940/4885CTSG 1162/4885CTRB1 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.